Abstract CT233: Initial Results of a Phase 1b/2 Study of ADG126 (a Masked Anti-Ctla-4 SAFEbody®) in Combination with Pembrolizumab (an Anti-Pd-1 Antibody) in Patients with Advanced/metastatic Solid Tumors
Cancer Research（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined